Table I.

Influence of dabigatran and rivaroxaban on some coagulation assays.

	Patients treated with dabigatran (n=3)		Patients treated with rivaroxaban (n=4)
	Baseline	With dabigatran	Baseline	With rivaroxaban
PT (sec)	16.7±3.11	20.17±3.24*	18.1±2.21	35.43±3.69**
aPTT (sec)	26.84±2.98	36.41±6.45*	27.99±3.12	35.05±5.82*
Fibrinogen (mg/dL)	383±84	360±33	348±96	327±90
TT (sec)	15.92±1.26	533±150***	16.73±1.01	19.21±1.61
APCr (ratio)	1.67±0.31	2.87±0.29**	1.81±0.27	1.35±0.21*
Antithrombin (%)	98±12	92±14	85±21	68±19*
Protein C (%)	93±27	99±22	95±24	98±21
Protein S (%)	102±19	102±21	91±23	88±17
Drug (ng/mL)		167±97		299±131

Results are reported as the mean ±1 SD.

Reference values: PT=10.7–14.6 sec; aPTT=23.2–30.9; TT=12–20.5 sec; fibrinogen=200–450 mg/dL; APCr= >2.2 normal subjects, from 1.2 to 2.2 in heterozygotes, <1.2 in homozygotes; antithrombin=80–120%; protein C=80–120%; free protein S=80–120%.

^*p<0.05,

^**p<0.01,

^***p<0.0001.

PT: prothrombin time; aPTT: activated partial thromboplastin time; TT: thrombin time; APCr: activated protein C resistance.